Department of Gastroenterology, Hepatology, and Endocrinology, 9177Hannover Medical School Hannover, Hannover, Germany.
Centre for Individualised Infection Medicine (CiiM), a joint venture of Helmholtz Centre for Infection Research and Hannover Medical School, Hannover, Germany.
Antivir Ther. 2022 Feb-Apr;27(1-2):13596535211072672. doi: 10.1177/13596535211072672.
The development of direct-acting antivirals (DAA) has revolutionized the treatment of chronic hepatitis C, enabling cure of hepatitis C virus (HCV) infection in more than 95% of cases. There are essentially no contraindications, so almost any patient can now be successfully treated. The result is the prevention or amelioration of cirrhosis, hepatocellular carcinoma (HCC), and extrahepatic manifestations. Consequently, the 2020 Nobel Prize in Medicine and Physiology was awarded for the discovery of HCV. Due to the high efficacy of therapy, even global HCV elimination is conceivable even without a vaccine. Here, we would like to venture a SWOT analysis of current HCV therapies aimed at HCV elimination.
直接作用抗病毒药物 (DAA) 的发展彻底改变了慢性丙型肝炎的治疗方法，使得超过 95%的丙型肝炎病毒 (HCV) 感染病例得以治愈。基本上没有禁忌症，因此现在几乎任何患者都可以成功治疗。其结果是预防或改善肝硬化、肝细胞癌 (HCC) 和肝外表现。因此，2020 年诺贝尔医学和生理学奖授予了 HCV 的发现者。由于治疗效果非常高，即使没有疫苗，也可以想象实现全球 HCV 的消除。在这里，我们希望对旨在消除 HCV 的当前 HCV 治疗方法进行 SWOT 分析。
